Drug resistance in Mexico: results from the National Survey on Drug-Resistant Tuberculosis

被引：21

作者：

Bojorquez-Chapela, I. ^{[1
]}

Baecker, C. E. ^{[2
]}

Orejel, I. ^{[3
]}

Lopez, A. ^{[4
]}

Diaz-Quinonez, A. ^{[2
,5
]}

Hernandez-Serrato, M. I. ^{[6
]}

Balandrano, S. ^{[2
]}

Romero, M. ^{[6
]}

Tellez-Rojo Solis, M. M. ^{[6
]}

Castellanos, M. ^{[3
,6
]}

Alpuche, C. ^{[6
]}

Hernandez-Avila, M. ^{[6
]}

Lopez-Gatell, H. ^{[6
]}

机构：

[1] Colegio Frontera Norte, Tijuana, Baja California, Mexico

[2] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico

[3] Ctr Nacl Programas Prevent & Control Enfermedades, Mexico City, DF, Mexico

[4] Inst Nacl Estadist & Geog, Aguascalientes City, Mexico

[5] Inst Mexicano Seguro Social, Mexico City, DF, Mexico

[6] Inst Nacl Salud Publ, Cuernavaca 62100, Morelos, Mexico

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2013年 / 17卷 / 04期

关键词：

pulmonary tuberculosis; multidrug-resistant tuberculosis; epidemiology; MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; PREVALENCE;

D O I：

10.5588/ijtld.12.0167

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

OBJECTIVE: To present estimations obtained from a population-level survey conducted in Mexico of prevalence rates of mono-, poly- and multidrug-resistant strains among newly diagnosed cases of pulmonary tuberculosis (TB), as well as the main factors associated with multidrug resistance (combined resistance to isoniazid and rifampicin). DESIGN: Study data came from the National Survey on TB Drug Resistance (ENTB-2008), a nationally representative survey conducted during 2008-2009 in nine states with a stratified cluster sampling design. Samples were obtained for all newly diagnosed cases of pulmonary TB in selected sites. Drug susceptibility testing (DST) was performed for anti-tuberculosis drugs. RESULTS: DST results were obtained for 75% of the cases. Of these, 82.2% (95%CI 79.5-84.7) were susceptible to all drugs. The prevalence of multidrug-resistant TB (MDR-TB) was estimated at 2.8% (95%CI 1.9-4.0). MDR-TB was associated with previous treatment (OR 3.3, 95%CI 1.1-9.4). CONCLUSIONS: The prevalence of drug resistance is relatively low in Mexico. ENTB-2008 can be used as a baseline for future follow-up of drug resistance.

引用

页码：514 / 519

页数：6

共 18 条

[1] Al-Akhali A, 2007, INT J TUBERC LUNG D, V11, P1328
[2] [Anonymous], 2008, WHO/HTM/TB/2008.394
[3] [Anonymous], 2011, GLOBAL TUBERCULOSIS
[4] [Anonymous], 2010, WHO/HTM/TB/2010.3
[5] Farga V, 2011, TUBERCULOSIS
[6] Risk factors for multidrug resistant tuberculosis in Europe: a systematic review
Faustini, A
Hall, AJ
Perucci, CA
[J]. THORAX, 2006, 61 (02) : 158 - 163
[7] Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997
Granich, RM
Balandrano, S
Santaella, AJ
Binkin, NJ
Castro, KG
Marquez-Fiol, A
Anzaldo, G
Zarate, M
Jaimes, ML
Velazquez-Monroy, O
Salazar, L
Alvarez-Lucas, C
Kuri, P
Flisser, A
Santos-Preciado, J
Ruiz-Matus, C
Tapia-Conyer, R
Tappero, JW
[J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) : 639 - 644
[8] High prevalence of multidrug-resistant tuberculosis in Georgia
Mdivani, Nino
Zangaladze, Ekaterina
Volkova, Natalia
Kourbatova, Ekaterina
Jibuti, Thea
Shubladze, Natalia
Kutateladze, Tamar
Khechinashvili, George
del Rio, Carlos
Salakaia, Archil
Blumberg, Henry M.
[J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (06) : 635 - 644
[9] Secretaria de Salud, 2005, NOM006SSA1993 SECR S
[10] SIDDIQI SH, 1989, BACTEC TB SYSTEM PRO

← 1 2 →